Plans to invest in a new Mumbai corporate office in Bandra Kurla Complex
Abbott plans to invest in a new Mumbai corporate office in the Godrej BKC building in the Bandra Kurla Complex that will allow it to consolidate existing offices and operations in Mumbai into a single location. It will occupy more than 400,000 sq ft of office space in Mumbai’s Bandra Kurla Complex, housing more than 1,500 employees. The company anticipates occupying the building starting in 2016.
Abbott also intends to expand manufacturing capacity and R&D capability, employee development and community programmes in India. The company will increase its infrastructure, capabilities and staff at both its pharmaceutical and nutrition R&D facilities to drive innovations and new product introductions in India. The Mumbai pharma development facility will also expand its development of new solutions for people across the rest of the world.
Through expansion of capacity at the pharma manufacturing plant in Baddi, Abbott is working to meet growing needs in India and also export branded generic pharma to other emerging markets in Southeast Asia and Africa.
Abbott is providing 1,500 small and rural dairy farmers with the support and infrastructure needed to increase their incomes and expand the supply of high-quality milk, with the aim of sourcing up to 80 per cent of Abbott’s nutrition product ingredients locally. Working with non-profit partners, the company will provide training on business skills and animal care, and building new milk chillers in 10 villages to help with efficient transport and storage.
Abbott is investing Rs 3.2 crores ($500,000) to improve sanitation in hundreds of homes, schools and community centers; raise community awareness of the connections between sanitation and health; and empower the communities in two villages in Bharuch District, Talodara and Dadheda, to maintain the new facilities.
By partnering with stakeholders to drive awareness, early detection and diagnosis, Abbott is helping to manage and lower the burden of diseases affecting people in India. For example, thyroid disorders are one of the commonly underdiagnosed chronic health conditions in India. Through the ‘Make India Thyroid Aware’ programme, Abbott in partnership with the Indian Thyroid Society, plans to reach out to over 2 million people through diagnosis and education camps across India in 2015 and 2016.
“India is one of the most important places in the world for Abbott, and we’re investing here accordingly,” said Miles D White, Chairman and Chief Executive Officer, Abbott.